NEW YORK (TheStreet) -- ManKind (MNKD) - Get Report shares are spiking, up 10.6% to $11.06, on Monday after the FDA approved the company's inhaled insulin drug Afrezza.

Wall Street analysts believe that the drug could generate peak yearly sales of $600 million for the company.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Image placeholder title

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.